ESMO 2017 Congress Videos

ESMO-2017-square

The ESMO 2017 Congress, in partnership with the European Association for Cancer Research (EACR), will bring cancer researchers and clinicians together to enable collaboration and the exchange of ideas, from the laboratory to the bedside and back.

Our scientific video reports bring an overview of the main results for a topic and a take home message from an expert to you!

Presentations (slides) and webcasts are available to ESMO members according to the presenters' agreement to release them. Abstracts are open access.

Access All Congress Resources

Filter

Sarcoma - GIST - Rare Cancers

ESMO 2017 Highlights in Sarcoma and GIST: Novel Drugs and Networks

  • 12 Sep 2017

Sebastian Bauer speaks about the importance of the results presented during ESMO 2017, both from the clinical research and patient management perspective. He reports some results presented by a French group showing that the local disease control is highly significantly better when patients are treated in a reference centre.

view detailsof ESMO 2017 Highlights in Sarcoma and GIST: Novel Drugs and Networks

Gastrointestinal Cancers - Gastric Cancer

ESMO 2017 Highlights in Upper GI Cancers: Clinically Relevant Combo Studies

  • 12 Sep 2017

Stefano Cascinu reports that practice changing results were presented for both resectable and advanced upper GI cancers during the ESMO 2017 Congress.

view detailsof ESMO 2017 Highlights in Upper GI Cancers: Clinically Relevant Combo Studies

Immunotherapy - Skin Cancers - Melanoma - Therapy

ESMO 2017 Highlights in Melanoma: Milestones in Adjuvant Treatment

  • 12 Sep 2017

Olivier Michielin discusses the results of 3 major adjuvant melanoma studies presented at the ESMO 2017 Congress.

view detailsof ESMO 2017 Highlights in Melanoma: Milestones in Adjuvant Treatment

Immunotherapy - Head and Neck Cancers - Therapy

ESMO 2017 Highlights in Head and Neck Cancer: Spotlight on Immunotherapy

  • 12 Sep 2017

Marco Merlano explains that head and neck cancer remains an interesting field of investigation for immunotherapy because these tumours have high mutational burden. Among all of the studies presented in Madrid, two results deserve more attention.

view detailsof ESMO 2017 Highlights in Head and Neck Cancer: Spotlight on Immunotherapy

Cancer Biology - Translational Research - Basic Scientific Principles - Basic Principles in the Management and Treatment (of cancer)

ESMO 2017 Highlights in Basic Science: Impressive Research by Young Investigators

  • 12 Sep 2017

Anton Berns explains that the EACR and ESMO partnership in this congress is welcome as research and clinical practice need each other. His selection of studies from very promising young investigators shows the interest of what they are doing in the field.

view detailsof ESMO 2017 Highlights in Basic Science: Impressive Research by Young Investigators

Gynaecological Malignancies - Ovarian Cancer - Cervical Cancer

ESMO 2017 Highlights in Gynaecological Cancers: Hight Quality Data From Randomised Trials

  • 12 Sep 2017

Mansoor Mirza comments on some very important results from phase III trials presented this year at the ESMO 2017 Congress. These findings confirm the standard of care for cervical and new or relapsed ovarian cancer.

view detailsof ESMO 2017 Highlights in Gynaecological Cancers: Hight Quality Data From Randomised Trials

Breast Cancer - Immunotherapy - Therapy

ESMO 2017 Highlights in Breast Cancer: Further Progress in ER+/HER2- Disease

  • 12 Sep 2017

Aleix Prat points out the importance of the results presented during the ESMO 2017 Congress for the breast cancer community.

view detailsof ESMO 2017 Highlights in Breast Cancer: Further Progress in ER+/HER2- Disease

Anticancer Agents - Immunotherapy - Genitourinary Cancers - Renal Cell Cancer - Urothelial Cancers - Prostate Cancer - Therapy - Biological Therapy

ESMO 2017 Highlights in Genitourinary Cancers: Treatment Advances

  • 12 Sep 2017

Bernard Escudier explains the results from the practice changing CheckMate 214 study that supports the use of combined nivolumab plus ipilimumab as a potential first-line treatment for patients with intermediate/poor risk metastatic renal cell carcinoma, particularly those patients having tumour PD-L1 expression ≥1%.

view detailsof ESMO 2017 Highlights in Genitourinary Cancers: Treatment Advances

Thoracic Malignancies - Mesothelioma - Rare Cancers

ESMO 2017 Highlights in Mesothelioma: Role of Immunotherapy in Second- and Third-Line of Treatment

  • 12 Sep 2017

Julien Mazières explains that while the first-line standard of care is clear, there are no clear recommendations for 2nd and 3rd line treatments.

view detailsof ESMO 2017 Highlights in Mesothelioma: Role of Immunotherapy in Second- and Third-Line of Treatment

Haematological Malignancies

ESMO 2017 Highlights in Haematological Malignancies: Emphasis on Biosimilars and t-AML

  • 12 Sep 2017

Michele Ghielmini talks about the level of importance given to biosimilars in this ESMO 2017 Congress and their activity in haematological malignancies.

view detailsof ESMO 2017 Highlights in Haematological Malignancies: Emphasis on Biosimilars and t-AML

Supportive and Palliative Care

ESMO 2017 Highlights in Supportive and Palliative Care: Focus on Patient Reported Outcomes

  • 12 Sep 2017

Karin Jordan says that supportive and palliative care issues are becoming increasingly important in oncology practice and that an ESMO position paper on this topic will be coming soon.

view detailsof ESMO 2017 Highlights in Supportive and Palliative Care: Focus on Patient Reported Outcomes